Structure-activity relationships for substrate-based inhibitors of human complement factor B

Journal of Medicinal Chemistry

Volumn 52, Issue 19, 2009, Pages 6042-6052

  Ruiz Gómez, Gloria ^a   Lim, Junxian ^a   Halili, Maria A ^a   Le, Giang T ^a   Madala, Praveen K ^a   Abbenante, Giovanni ^a   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE INHIBITOR DERIVATIVE; COMPLEMENT MEMBRANE ATTACK COMPLEX; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG STABILITY; DRUG SYNTHESIS; HEMOLYSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR B; COMPLEMENT PATHWAY, ALTERNATIVE; ERYTHROCYTES; HEMOLYSIS; HUMANS; MOLECULAR MIMICRY; OLIGOPEPTIDES; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349640052     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900781m     Document Type: Article

References (68)

1. Fearon, D. T.; Locksley, R. M. The Instructive Role of Innate Immunity in the Acquired Immune Response. Science 1996, 272, 50-54.
2. Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 2001, 344, 1058-1066.
3. Morgan, B. P.; Harris, C. L. Complement Therapeutics; History and Current Progress. Mol. Immunol. 2003, 40, 159-170.
4. Carroll, M. C. The Complement System in Regulation of Adaptive Immunity. Nat. Immunol. 2004, 5, 981-986.
5. Volanakis, J. E. Overview of the Complement System. In The Human Complement System in Health and Disease; Volanakis, J. E. Frank, M. M., Eds.; Marcel Dekker, Inc.: New York, 1998; pp 9-32.
6. Sim, R. B.; Tsiftsoglou, S. A. Proteases of the Complement System. Biochem. Soc. Trans. 2004, 32, 21-27.
7. Gros, P.; Milder, F. J.; Janssen, B. J. Complement Driven by Conformational Changes. Nat. Rev. Immunol. 2008, 8, 48-58.
8. Muller-Eberhard, H. J. The Membrane Attack Complex of Complement. Annu. Rev. Immunol. 1986, 4, 503-528.
9. Sahu, A.; Kay, B. K.; Lambris, J. D. Inhibition of Human Complement by a C3-Binding Peptide Isolated from a Phage-Displayed Random Peptide Library. J. Immunol. 1996, 157, 884-891.
10. Kerr, M. A. Factor B and the Alternative Pathway C3/C5 Convertase. In Handbook of Proteolytic Enzymes, 2nd ed.; Barrett, A. J., Rawlings, N. D., Woessner, J. F., Eds.; Elsevier: London, 2004, vol.2, pp 1632-1637.
11. Volanakis, J. E.; Narayana, S. V. Complement Factor D, a Novel Serine Protease. Protein Sci. 1996, 5, 553-564.
12. Hourcade, D. E. The Role of the Properdin in the Assembly of the Alternative Pathway C3 Convertases of Complement. J. Biol. Chem. 2006, 281, 2128-2132.
13. Hourcade, D. E. Properdin and Complement Activation: A Fresh Perspective. Curr. Drug Targets 2008, 9, 158-164.
14. Mole, J. E.; Anderson, J. K.; Davison, E. A.; Woods, D. E. Complete Primary Structure for the Zymogen of Human Complement Factor B. J. Biol. Chem. 1984, 259, 3407-3412.
15. Xu, Y.; Narayana, S. V.; Volanakis, J. E. Structural Biology of the Alternative Pathway Convertase. Immunol. Rev. 2001, 180, 123-135.
16. Law, S. K.; Reid, K. B. M. Complement; 2nd ed.; IRL Press: Oxford, 1995.
17. Pryzdial, E. L.; Isenman, D. E. Alternative Complement Pathway Activation Fragment Ba Binds to C3b. Evidence that Formation of the Factor B-C3b Complex Involves Two Discreate Points of Contact. J. Biol. Chem. 1987, 262, 1519-1525.
18. 2O)-Factor B Complex of the Alternative Pathway of Complement. Biochem. Soc. Trans. 1994, 22, 2S.
19. Curman, B.; Sandberg-Tragardh, L.; Peterson, P. A. Chemical Characterization of Human Factor B of the Alternate Pathway of Complement Activation. Biochemistry 1977, 16, 5368-5375. (Pubitemid 8241860)
20. Kerr, M. A. Limited Proteolysis of Complement Component C2 and Factor B. Structural Analogy and Limited Sequence Homology. Biochem. J. 1979, 183, 615-622.
21. Fishelson, Z.; Pangburn, M. K.; Muller-Eberhard, H. C. Characterization of the Initial C3 Convertase of the Alternative Pathway of Human Complement. J. Immunol. 1984, 132, 1430-1434. (Pubitemid 14154572)
22. Fishelson, Z.; Pangburn, M. K.; Muller-Eberhard, H. J. C3 Convertase of the Alternative Complement Pathway. Demonstration of an Active, Stable C3b,Bb (Ni) Complex. J. Biol. Chem. 1983, 258, 7411-7415.
23. Taniguchi-Sidle, A.; Isenman, D. E. Interaction of Human Complement C3 with Factor B and with Complement Receptors Type 1 (CR1, CD35) and Type 3 (CR3, CD11b/CD18) Involve an Acidic Sequence at the N-Terminus of C3-Alpha0-Chain. J. Immunol. 1994, 153, 5285-5302. (Pubitemid 24983929)
24. Kolln, J.; Spillner, E.; Andra, J.; Klensang, K.; Bredehorst, R. Complement Inactivation by Recombinant Human C3 Derivates. J. Immunol. 2004, 173, 5540-5545. (Pubitemid 39392140)
25. Kolln, J.; Bredehorst, R.; Spillner, E. Engineering of Human Complement Component C3 for Catalytic Inhibition of Complement. Immunol. Lett. 2005, 98, 49-56.
26. Hourcade, D. E.; Wagner, L. M.; Oglesby, T. J. Analysis of the Short Consensus Repeats of Human Complement Factor B by Site- Directed Mutagenesis. J. Biol. Chem. 1995, 270, 19716-19722.
27. Hourcade, D. E.; Mitchell, L. M.; Oglesby, T. J. Mutations of the Type A Domain of Complement Factor B that Promote High- Affinity C3b-Binding. J. Immunol. 1999, 162, 2906-2911.
28. Hinshelwood, J.; Spencer, D. I.; Edwards, Y. J.; Perkins, S. J. Identification of the C3b Binding Site in a Recombinant vWF-A Domain of Complement Factor B by Surface-Enhanced Laser Desorption-Ionisation Affinity Mass Spectrometry and Homology Modelling: Implications for the Activity of Factor B. J. Mol. Biol. 1999, 294, 587-599.
29. Emsly, J.; Knight, C. G.; Farndale, R. W.; Barnes, R. W.; Liddington, R. C. Structural Basis of Collagen Recognition by Integrin α2β1. Cell 2000, 101, 47-56.
30. Bhattacharya, A. A.; Lupher, M. L.; Staunton, D. E.; Liddington, R. C. Crystal Structure of the A Domain from Complement Factor B Reveals an Integrin-like Open Conformation. Structure 2004, 12, 371-378.
31. Springer, T. A. Complement and the Multifaceted Functions of VWA and Integrin I Domains. Structure 2006, 14, 1611-1616.
32. Lambris, J. D.; Muller-Eberhard, H. J. Isolation and Characterization of a 33000-Dalton Fragment of Complement Factor B with Catalytic and C3b Binding Activity. J. Biol. Chem. 1984, 259, 12685-12690.
33. Milder, F. J.; Gomes, L.; Schouten, A.; Janssen, B. J. C.; Huizinga, E. G.; Romijn, R. A.; Hemrika, W.; Roos, A.; Daha, M. R.; Gros, P. Factor B Structure Provides Insights into Activation of the Central Protease of the Complement System. Nat. Struct. Mol. Biol. 2007, 14, 224-228.
34. Ponnuraj, K.; Xu, Y.; Macon, K.; Moore, D.; Volanakis, J. E.; Narayana, S. V. L. Structural Analysis of Engineered Bb Fragment of Complement Factor B: Insights into the Activation Mechanism of the Alternative Pathway C3-Convertase. Mol. Cell 2004, 14, 17-28.
35. Thurman, J. A.; Krausb, D. M.; Girardic, G.; Hourcaded, D.; Kang, H. J.; Royer, P. A.; Mitchell, L. M.; Giclas, P. C.; Salmon, J.; Gikelson, G.; Holers, V. M. A Noel Inhibitor of the Alternative Complement Pathway Prevents Antiphospholipid Antibody- Induced Pregnancy Loss in Mice. Mol. Immunol. 2005, 42, 87-97.
36. Taube, C.; Thurman, J. M.; Takeda, K.; Joetham, A.; Miyahara, N.; Carroll, M. C.; Dakhama, A.; Giclas, P. C.; Holers, V. M.; Gelfand, E. W. Factor B of the Alternative Complement Pathway Regulates Development of Airway Hyperresponsiveness and Inflammation. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 8084-8089.
37. Thurman, J. M.; Holers, V. M. The Central Role of the Alternative Complement Pathway in Human Disease. J. Immunol. 2006, 176, 1305-1310.
38. Sidonia, M.; Chiriac, M. T.; Takahashi, K.; Thurman, J. M.; Holers, V. M.; Zillikens, D.; Botto, M.; Sitarau, C. The Alternative Pathway of Complement Activation Is Critical for Blister Induction in Experimental Epidermolysis Bullosa Acquisita. J. Immunol. 2007, 178, 6514-6521.
39. Thurman, J. M.; Ljubanovic, D.; Edelstein, C. L.; Gilkeson, G. S.; Holers, V. M. Lack of a Functional Alternative Complement Pathway Ameliorates Ischemic Acute Renal Failure in Mice. J. Immunol. 2003, 170, 1517-1523.
40. Ji, H.; Ohmura, K; Mahmood, U.; Lee, D. M.; Hofhuis, F. M.; Boackle, S. A.; Takahashi, K.; Holers, V. M.; Walport, M.; Gerard, C.; Ezekowitz, A.; Carrol, M. C.; Brenner, M.; Weissleder, R.; Verbeek, J. S.; Duchatelle, V.; Degott, C.; Benoist, C.; Mathis, D. Arthritis Critically Dependent on Innate Immune System Players. Immunity 2002, 16, 157-168. (Pubitemid 34211957)
41. Thurman, J. M.; Joetham, A.; Balhorn, A.; Swasey, C.; Dakhama, A. et al. et al. 20th International Complement Workshop, Honolulu, HI, June 13-18, 2004. Vogel, C. W., Ed.; Mol. Immunol. 2004, 41, 319.
42. Elliot, M. K.; Jarmi, T.; Ruiz, P.; Xu, Y. Y.; Holers, V. M.; Gilkeson, G. S. Effects of Complement Factor D Deficiency on the Renal Disease of MRL/lpr Mice. Kidney Int. 2004, 65, 129-138. (Pubitemid 38037497)
43. Leinhase, I.; Rozanski, M.; Harhausen, D.; Thurman, J. M.; Schmidt, O. I.; Hossini, A. M.; Taha, M. E.; Rittirsch, D.; Ward, P. A.; Holers, V. M.; Ertel, W.; Stahel, P. F. Inhibition of the Alternative Complement Activation Pathway in Traumatic Brain Injury by a Monoclonal Anti-Factor B Antibody: a Randomized Placebo-Controlled Study in Mice. J. Neuroinflamm. 2007, 4, 13.
44. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease Inhibitors: Current Status and Future Prospects. J. Med. Chem. 2000, 43, 305-341.
45. Abbenante, G.; Fairlie, D. P. Protease Inhibitors in the Clinic. Med. Chem. 2005, 1, 71-104.
46. Inagi, R.; Miyata, T.; Maeda, K.; Sugiyama, S.; Piyama, A.; Nakashima, I. FUT-175 as a Potent Inhibitor of C5/C3 Convertase Activity for Production of C5a and C3a. Immunol. Lett. 1991, 27, 49-52.
47. Morikis, D.; Assa-Munt, N.; Sahu, A.; Lambris, J. D. Solution Structure of Compstatin, a Potent Complement Inhibitor. Protein Sci. 1998, 7, 619-627. (Pubitemid 28130884)
48. Soulika, A. M.; Holland, M. C.; Sfyroera, G.; Sahu, A.; Lambris, J. Compstatin Inhibits Complement Activation by Binding to the β-Chain of Complement Factor 3. Mol. Immunol. 2006, 43, 2023-2029.
49. Ueda, N.; Midorikawa, A.; Ino, Y.; Oda, M.; Nakamura, K.; Suzuki, S.; Kurumi, M. Inhibitory Effects of Newly Synthesized Active Center-Directed Trypsin-like Serine Protease Inhibitors on the Complement System. Inflamm. Res. 2000, 49, 42-46.
50. Furlong, S. T.; Dutta, A. S.; Coath, M. M.; Gormley, J. J.; Hubbs, S. J.; Lloyd, D.; Mauger, R. C.; Strimpler, A. M.; Sylvester, M. A.; Scott, C. W.; Edwards, P. D. C3 Activation Is Inhibited by Analogs of Compstatin but Not by Serine Protease Inhibitors or Peptidyl α-Ketoheterocycles. Immunopharmacology 2000, 48, 199-212.
51. Le, G. T.; Abbenante, G.; Fairlie, D. P. Profiling the Enzymatic Properties and Inhibition of Human Complement Factor B. J. Biol. Chem. 2007, 282, 34809-34816.
52. Leung, D.; Schroder, K.; White, H.; Fang, N. X.; Stoermer, M. J.; Abbenante, G.; Martin, J. L.; Young, P. R.; Fairlie, D. P. Activity of Recombinant Dengue 2 Virus NS3 Protease in the Presence of a Truncated NS2B Co-Factor, Small Peptide Substrates, and Inhibitors. J. Biol. Chem. 2001, 276, 45762-45771.
53. Nall, T. A.; Chappell, K. J.; Stoermer, M. J.; Fang, N. X.; Tyndall, J. D. A.; Young, P. R.; Fairlie, D. P. Enzymatic Characterization and Homology Model of a Catalytically Active Recombinant West Nile Virus NS3 Protease. J. Biol. Chem. 2004, 279, 48535-48542.
54. Li, J.; Lim, S. P.; Beer, D.; Patel, V.; Wen, D. Y.; Tumanut, C.; Tully, D. C.; Williams, J. A.; Jiricek, J.; Priestle, J. P.; Harris, J. L.; Vasudevan, S. G. Functional Profiling of Recombinant NS3 Proteases from All Four Serotypes of Dengue Virus Using Tetrapeptide and Octapeptide Substrate Libraries. J. Biol. Chem. 2005, 280, 28766-28774.
55. Fairlie, D. P.; Tyndall, J. D. A.; Reid, R. C.; Wong, A. K.; Abbenante, G.; Scanlon, M. J.; March, D. R.; Bergman, D. A.; Chai, C. L. L.; Burkett, B. A. Conformational Selection of Inhibitors and Substrates by Proteolytic Enzymes: Implications for Drug Design and Polypeptide Processing. J. Med. Chem. 2000, 43, 1271-1281.
56. Tyndall, J. D. A.; Nall, T.; Fairlie, D. P. Proteases Universally Recognize Beta Strands in their Active Sites. Chem. Rev. 2005, 105, 973-999.
57. Siev, D. V.; Semple, J. E. Novel Hydrazino-Carbonyl-Amino- Methylated Polystyrene (HCAM) Resin Methodology for the Synthesis of P1-Aldehyde Protease Inhibitor Candidates. Org. Lett. 2000, 2, 19-22.
58. Jurczak, J.; Golebiowski, A. Optically active N-protected alpha-amino aldehydes in organic synthesis. Chem. Rev. 1989, 89, 149-164.
59. Fehrentz, J.-A.; Pothion, C.; Califano, J.-C.; Leffet, A.; Martinez, J. Synthesis of Chiral N-Protected α-Amino Aldehydes by Reduction of N-Protected N-Carboxyanhydrides (UNCAs). Tetrahedron Lett. 1994, 35, 9031-9034. (Pubitemid 24367836)
60. Gryko, D.; Chalko, J.; Jurczak, J. Synthesis and Reactivity of N-Protected α-Amino Aldehydes. Chirality 2003, 15, 514-541.
61. Arginine aldehyde peptides exist in solution in three interconverting forms and were obtained as a mixture of aldehyde, aldehyde hydrate and the corresponding cyclanol derivate, as normally observed: Tumori, E.; Horváth, Gy.; Sándor, P.; Koltai, E. Equilibrium Structures of the Arg-Aldehyde Moiety upon HPLC of Peptides. Chromatographia 1989, 27, 228-232.
62. 2H has been used where the cleaved bond in the catalytic site is defined between the P1 and P1′ residues: Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
63. Deppisch, R.; Schmitt, V.; Bommer, J.; Hansch, G. M.; Ritz, E.; Rauterberg, E. W. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int. 1990, 37, 696-706.
64. Powell, M. J. D. Restart Procedures for the Conjugate Gradient Method. Math. Program. 1977, 12, 241-254
65. Clark, M.; Cramer, R. D., III; van Opdenbosch, N. J. Comput. Chem. 1989, 10, 982-1012.
66. Jones, G.; Willett, P.; Glen, R. C. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748
67. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for Detection of Free Terminal Amino Groups in the Solid-Phase Synthesis of Peptides. Anal. Biochem. 1970, 34, 595-598.
68. Shepherd, N. E.; Hoang, H. N.; Abbenante, G.; Fairlie, D. Single Turn Peptide Alpha Helices with Exceptional Stability in Water. J. Am. Chem. Soc. 2005, 127, 2974-2983.